Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: The 'sendo experience'

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1416-1421

  Mandala M ^a   Clerici, M ^b   Corradino, I ^b   Vitalini, C ^b   Colombini, S ^b   Torri, V ^c   De Pascale, A ^b   Marsoni, S ^b  

^a OSPEDALI RIUNITI   (Italy)

^b SENDO   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cancer; Phase I studies; Toxicity; Venous thromboembolism

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CONFIDENCE INTERVAL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KHORANA SCORE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATIENT INFORMATION; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; VENOUS THROMBOEMBOLISM;

EID: 84861732267     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr524     Document Type: Article

References (18)

1. Rickels FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 1: 237-248.
2. Kahn SR, Ducruet T, Lamping DL et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med 2005; 165: 1173-1178.
3. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 2005; 16: 696-701.
4. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
5. Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 2009; 27: 105-115.
6. Chew HK, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
7. Mandala M, Barni S, Floriani I et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer 2009; 45: 65-73.
8. Vemulapalli S, Chintala L, Tsimberidou AM. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a phase I clinic: the M. D. Anderson Cancer Center experience. Am J Hematol 2009; 84: 408-413.
9. Kuenen BC, Rosen L, Smit EF et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657-1667.
10. Ay C, Simanek R, Vormittag R et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112: 2703-2708.
11. Moore RA, Adel N, Riedel E et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29: 3466-3473.
12. Cassier PA, Moreno Garcia V, Gomez-Roca C. Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study Proceedings of the American Society of Clinical Oncology. J Clin Oncol 2011; 29 (Suppl): (Abstr 3084).
13. Khorana AA, Francis CW, Culakova E et al. Thrombeombolism in hospitalised neutropenia cancer patients. J Clin Oncol 2006; 24: 484-490.
14. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
15. Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2010; 19 (Suppl 2): ii126-ii127.
16. Levine M, Hirsh J, Gent M et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889.
17. Haas S, Kakkar AK, Kemkes-Matthes B. Prevention of venous thromboembolism with low molecular weight heparin in patients with metastatic breast or lung cancer-results of the TOPIC studies. ISTH 2005.
18. Agnelli G, Gussoni G, Bianchini C et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943-949.